Traders should monitor the AACR presentation for additional clinical details and watch for updates on Immatics' planned pediatric development program, which could expand the addressable market for its PRAME-directed therapies and support future trial designs or partnerships.
Price Chart
Executive Summary
Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nephroblastoma after treatment with its PRAME-directed TCR T-cell therapy (IMA203CD8) under a named-patient use program. The case, to be presented at AACR 2026, demonstrates strong anti-tumor activity across multiple metastatic sites and supports the potential of PRAME-targeted cell therapy in pediatric solid tumors.
Key Facts
- 17-year-old pediatric patient with PRAME-positive nephroblastoma achieved deep remission after treatment with Immatics' IMA203CD8 TCR T-cell therapy.
- Remission included marked regression of liver, lung, and brain metastases, ongoing at 6 months post-infusion.
- Molecular remission confirmed via liquid biopsy with no detectable tumor-derived DNA.
- Safety events included manageable cytokine release syndrome resolved with standard therapy.
- Data to be presented in a late-breaking poster at AACR Annual Meeting 2026.
- Immatics plans a potential Phase 1/2 basket study in pediatric patients with PRAME-positive solid tumors.
Financial Impact
No direct financial impact disclosed, but significant strategic and clinical validation for Immatics' PRAME platform.
Risk Factors
- Single-patient case study with no control group; results may not be reproducible.
- Named-patient use is not a controlled clinical trial; regulatory path remains uncertain.
- Forward-looking statements about future trials and commercial potential are subject to development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276451 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.72 (−18.25%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.72 (+17.47%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.72 (−15.02%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.72 (−15.02%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.72 (−23.06%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.72 (+32.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access